Our team is studying systemic lupus erythematosus (SLE) at both molecular and cellular levels with the aim of understanding the key elements leading to the break of tolerance and to generate new druggable molecules immunoregulating its evolution.
The group concentrates its activity on effector cells and death/survival factors involved in lupus triggering. In this context, we focus on the central role of autoantigen in the pathophysiology of lupus and more particularly on apoptosis-specific post-translational modifications occurring in autoantigens. Our project also concerns the impact of autophagy on the development of lupus pathology in relation with the presentation by antigen-presenting cells of class II antigens to autoreactive T cells. The therapeutic peptide P140 developed in our team is a possible modulator of autophagy processes. Our ongoing work aims at deciphering the molecular mechanisms used by P140 peptide to alter self-peptide presentation to autoreactive T cells and hamper their deleterious activation in lupus.
The group is a member of the French-speaking club of autophagy.
Systemic lupus erythematosus
Post-translational modifications on lupus autoantigens during apoptosis
Implication of macroautophagy in autoimmune diseases
Development of a tolerogenic peptide for treating lupus
Modulating class II antigens presentation as a strategy to modulate autoimmune diseases
Development of an innovative vector for oral delivery of peptides